Previous 10 | Next 10 |
2024-05-13 13:53:13 ET More on AstraZeneca, Pfizer Pfizer's Bottom May Be Here - Its Rich Yield Is Tempting Pfizer: A 6% Yield And At 10-Year Lows Pfizer Stock: Not A Value Trap, Here's Why Pfizer to settle over 10,000 Zantac-related cancer claims: report ...
2024-05-13 10:09:30 ET More on Sanofi, Fulcrum Sanofi Q1: Wait And See For Now (Downgrade) Sanofi: Q1 Earnings Reflect Growth And Strategic Acquisitions (Rating Upgrade) Sanofi 2024 Q1 - Results - Earnings Call Presentation Biggest stock movers today: ARM, ZK...
― Entered into a collaboration and ex-U.S. license agreement with Sanofi for the development and commercialization of losmapimod ― ― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in the fourt...
― Sanofi receives exclusive rights to commercialize losmapimod in all territories outside the U.S.; Fulcrum retains full U.S. commercialization rights ― ― Fulcrum will receive an upfront payment of $80.0 million, and is eligible to receive $975.0 million in potentia...
2024-05-13 05:49:56 ET More on related stocks: Novavax: Sanofi Partnership Revitalizes My Magnum Opus Novavax, Inc. (NVAX) Q1 2024 Earnings Call Transcript Spotlight On The CPI Print, Walmart Earnings, Google Event And Zeekr Buzz Sanofi to invest over €...
2024-05-13 03:29:35 ET More on Sanofi Sanofi Q1: Wait And See For Now (Downgrade) Sanofi: Q1 Earnings Reflect Growth And Strategic Acquisitions (Rating Upgrade) Sanofi 2024 Q1 - Results - Earnings Call Presentation Novavax surges as Sanofi COVID vaccine deal ...
If approved, Dupixent would be the first treatment in the U.S. indicated for adolescents aged 12-17 years with inadequately controlled CRSwNP, a condition driven in part by underlying type 2 inflammation that obstructs the sinuses and nasal passages and can lead to a loss of sense of smell ...
2024-05-12 13:07:18 ET Summary Novavax announced Q1 2024 results with a beat on EPS and a miss on revenue, causing a surge in premarket trading. Novavax finalized a licensing agreement with Sanofi worth up to $1.2B, boosting its COVID-19 vaccine commercial performance. The San...
2024-05-11 23:18:05 ET Summary IGM Biosciences is developing a different class of antibodies to improve on the classic IgG antibodies. Their most advanced project, aplitabart, is being tested in a clinical trial for metastatic colorectal cancer. The company has a decent cash p...
2024-05-11 07:59:50 ET More on Novavax Novavax Ditches 'Going Concern,' Embraces Sanofi Safety Net (Rating Upgrade) Novavax Q1 2024 Earnings Preview: Success In New Commercial COVID Markets Unlikely Novavax, Inc. (NVAX) TD Cowen's 44th Annual Health Care Conference -...
News, Short Squeeze, Breakout and More Instantly...
Sanofi ships U.S. influenza vaccines for the 2024/25 season PR Newswire Customers will start receiving shipments from July 10 with additional shipments through October to healthcare provider offices, pharmacies and other immunizers to support fall immunization campaigns. ...
2024-07-09 06:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...